Orphan Star Therapeutics Secures $20M Commitment

orphanOrphan Star Therapeutics, a NYC-based biopharmaceutical company focused on developing innovative therapies for rare diseases, secured a commitment of $20m from an unnamed commercial pharmaceutical partner.

The company intends to use the funds to advance its early-stage pipeline of innovative candidates for several rare diseases, including Canavan Disease, a devastating rare genetic neurodegenerative disease that is usually fatal within the first decade of life, and to complement its early-stage portfolio with promising clinical-stage drug candidates through building strategic partnerships within industry and academia.

Led by Dr. Nick France, Founder & CEO, Orphan Star is a biopharmaceutical company focused on the development of innovative therapies for rare genetic diseases.
The company, which is currently building a portfolio of early-stage drug candidates for rare neurometabolic diseases, has strengthened its team through the appointment of key hires, including:
– Adam Simpson, PhD, as Head of Business Development, and
– Katie St. Ledger, as Senior Director of Clinical Research and Development.

It also announced the appointment of Scientific Advisory Board Members Professor Paola Leone, PhD, an expert in Canavan disease and gene therapy for rare neurodegenerative disorders, and Prof. Dr. Alex Veldman, am academic, innovative drug developer and pediatrician.

FinSMEs

26/09/2018

Join the discussion